Status:
UNKNOWN
Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection
Lead Sponsor:
Bayside Health
Collaborating Sponsors:
University of Adelaide
Conditions:
Hepatitis C
Eligibility:
All Genders
18-70 years
Brief Summary
The purpose of this study is to examine gene expression profiles by DNA microarray in patients who are responders and non-responders to interferon and ribavirin treatment for hepatitis C virus (HCV). ...
Detailed Description
Background and Research Plan: Chronic HCV infection often follows a progressive course over many years, and can ultimately result in cirrhosis and the need for liver transplantation or hepatocellular...
Eligibility Criteria
Inclusion
- HCV mono-infection, no coagulopathy and having a liver biopsy for consideration of treatment
Exclusion
- Infection with HIV or HBV, excess ethanol (EtOH) consumption and other diseases of the liver
Key Trial Info
Start Date :
February 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00164073
Start Date
February 1 2004
End Date
February 1 2007
Last Update
August 1 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alfred Hospital
Melbourne, Victoria, Australia, 3181